Heart failure & cardiomyopathies
Acylation-Stimulating Protein and Heart Failure Progression in Arrhythmogenic Right Ventricular Cardiomyopathy
Main finding · HFAEs predicted by plasma ASP (multivariable Cox)Result — go to the resultHazard ratio 1.004 95% CI 1.002,1.006Authors' conclusion
Our results suggest that plasma ASP may be a useful biomarker in prediction of adverse HF-associated events in ARVC patients.
Study context
- Population
- Patients with arrhythmogenic right ventricular cardiomyopathy and healthy volunteers
- Participants
- 111 vs 106
- Exposure
- Arrhythmogenic right ventricular cardiomyopathy (ARVC) patients vs healthy volunteers; plasma acylation-stimulating protein (ASP) as predictor of HF-associated events
- ARVCn = 111
- Healthy controlsn = 106reference
- Outcome
- HF-associated events:
- Heart transplantation
- On a cardiac transplant list
- Death due to end-stage HF
- Follow-up
- Mean 17.79 ± 1.09 months
Main finding
As reported in the abstract
HFAEs predicted by plasma ASP (multivariable Cox)
Hazard ratio
1.004
95% CI 1.002,1.006
P = 0.002
ASP level
HR 1.004 (95% CI 1.002,1.006); P = 0.002
Observational data: associations, not effects.
Further findings
| Outcome | ARVC | Healthy controls | P value |
|---|---|---|---|
| Plasma ASP level, ARVC vs healthy controlsSimilar trend in myocardial explant assay | 2325.22 ± 20.08 | 2189.75 ± 15.55 | P < 0.001 |
| Plasma ASP by clinical events in ARVCHFAEs vs No clinical events | P < 0.001 | ||
| Plasma ASP by clinical events in ARVCHFAEs vs Malignant arrhythmic events | P = 0.008 |
- Plasma ASP by clinical events in ARVC: Heart failure-associated events (HFAEs) 2486.03 ± 26.70
- Plasma ASP by clinical events in ARVC: No clinical events 2268.83 ± 23.51
- Plasma ASP by clinical events in ARVC: Malignant arrhythmic events 2297.80 ± 60.46
Correlation of plasma ASP with remodelling in ARVC (Spearman)
- Associated with RV internal dimension
- P = 0.006
- Associated with LVEF
- P = 0.002
Original publication
Acylation-Stimulating Protein and Heart Failure Progression in Arrhythmogenic Right Ventricular Cardiomyopathy. ESC Heart Fail. Published 31 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →